OSE Immunotherapeutics Dirección

Dirección controles de criterios 3/4

El CEO de OSE Immunotherapeutics es Nicolas Poirier , nombrado en Jan 2016, tiene una permanencia de 8.83 años. compensación anual total es €440.10K, compuesta por 68.2% salario y 31.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.58% de las acciones de la empresa, por valor de €3.40M. La antigüedad media del equipo directivo y de la junta directiva es de 6.4 años y 2.4 años, respectivamente.

Información clave

Nicolas Poirier

Chief Executive Officer (CEO)

€440.1k

Compensación total

Porcentaje del salario del CEO	68.2%
Permanencia del CEO	8.8yrs
Participación del CEO	1.6%
Permanencia media de la dirección	6.4yrs
Promedio de permanencia en la Junta Directiva	2.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Nicolas Poirier en comparación con los beneficios de OSE Immunotherapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	€46m
Mar 31 2024	n/a	n/a	€12m
Dec 31 2023	€440k	€300k	-€23m
Sep 30 2023	n/a	n/a	-€25m
Jun 30 2023	n/a	n/a	-€28m
Mar 31 2023	n/a	n/a	-€23m
Dec 31 2022	€1m	n/a	-€18m
Sep 30 2022	n/a	n/a	-€13m
Jun 30 2022	n/a	n/a	-€7m
Mar 31 2022	n/a	n/a	-€12m
Dec 31 2021	€18k	n/a	-€17m
Sep 30 2021	n/a	n/a	-€21m
Jun 30 2021	n/a	n/a	-€25m
Mar 31 2021	n/a	n/a	-€21m
Dec 31 2020	€19k	n/a	-€17m
Sep 30 2020	n/a	n/a	-€12m
Jun 30 2020	n/a	n/a	-€8m
Mar 31 2020	n/a	n/a	-€6m
Dec 31 2019	€9k	n/a	-€5m

Compensación vs. Mercado: La compensación total de Nicolas($USD472.41K) está por debajo de la media de empresas de tamaño similar en el mercado UK ($USD747.77K).

Compensación vs. Ingresos: La compensación de Nicolas ha sido consistente con los resultados de la empresa en el último año.

CEO

Nicolas Poirier (42 yo)

8.8yrs

Permanencia

€440,100

Compensación

Dr. Nicolas Poirier, PhD, has been the Scientific Director of OSE Immunotherapeutics SA since 2016 and serves as its Director from June 26, 2019 and also serves as its General Director & Chief Executive Of...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Nicolas Poirier	General Director	8.8yrs	€440.10k	1.58% € 3.4m
Anne-Marie Costantini	Founder & Director of Development & Strategy	12.8yrs	€412.50k	9.23% € 19.9m
Anne-Laure Autret-Cornet	CFO, Administrative & Financial Director and Employee Shareholder Representative Director	8.5yrs	sin datos	sin datos
Alexis Peyroles	Consultant	2.8yrs	€586.59k	sin datos
Alain Chatelin	Medical Director	no data	sin datos	sin datos
Bérangère Vasseur	Chief Medical Officer Immuno-Oncology	6.8yrs	sin datos	sin datos
Julien Perrier	Chief Commercial Officer	5.9yrs	sin datos	sin datos
Linda Lebon	Chief Regulatory Officer	2.9yrs	sin datos	sin datos
Silvia Comis	Head of Clinical Development	2.9yrs	sin datos	sin datos
Jean-Jacques Mention	Chief Business Officer	no data	sin datos	sin datos

6.4yrs

Permanencia media

54yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0RAD es experimentado (6.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Nicolas Poirier	General Director	5.4yrs	€440.10k	1.58% € 3.4m
Anne-Laure Autret-Cornet	CFO, Administrative & Financial Director and Employee Shareholder Representative Director	1.4yrs	sin datos	sin datos
Maryvonne Hiance	Vice Chairwoman	8.5yrs	€25.71k	1.95% € 4.2m
Bernard Malissen	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Sophie Brouard	Director of External Affairs & Member of the Scientific Advisory Board	2.4yrs	€25.71k	sin datos
Charles Serhan	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Brigitte Dreno	Independent Director	7.4yrs	€21.43k	sin datos
Didier Hoch	Independent Chairman of the Board of Directors	8.5yrs	€28.57k	sin datos
Wolf-Herve Fridman	Chairman of the Scientific Board	11yrs	sin datos	sin datos
Jennifer Wargo	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Myriam Merad	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Eric Leire	Independent Director	1.4yrs	€15.00k	sin datos

2.4yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de 0RAD no se considera experimentada (2.4 años de permanencia promedio), lo que sugiere una nueva junta directiva.

OSE Immunotherapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

OSE Immunotherapeutics SA, Annual General Meeting, Jun 19, 2024

High number of new directors

High number of new directors

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

Recent updates

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: €2.63 (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco

Forecast breakeven date moved forward to 2024

OSE Immunotherapeutics SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: €1.18 loss per share (vs €0.96 loss in FY 2022)

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

New minor risk - Share price stability

New minor risk - Shareholder dilution

OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody

First half 2023 earnings released: €0.64 loss per share (vs €0.11 loss in 1H 2022)

Forecast breakeven date moved forward to 2024

New major risk - Financial position

High number of new directors

OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation

OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist

High number of new directors

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

OSE Immunotherapeutics SA Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announces Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer

Forecast to breakeven in 2025

Full year 2022 earnings released: €0.96 loss per share (vs €0.93 loss in FY 2021)

OSE Immunotherapeutics SA Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas

OSE Immunotherapeutics SA Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

Ose Immunotherapeutics Announces Publication of Peer-Reviewed Data on Clec-1

Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome

OSE Immunotherapeutics SA Updates on Tedopi®, Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

First half 2022 earnings released: €0.11 loss per share (vs €0.64 loss in 1H 2021)

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022

OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

OSE Immunotherapeutics SA Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

No longer forecast to breakeven

OSE Immunotherapeutics SA to Report Fiscal Year 2021 Results on Mar 30, 2022

Boehringer Ingelheim and OSE Immunotherapeutics to Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

OSE Immunotherapeutics SA Appoints Alexandre Lebeaut as Independent Member of the Board of Directors

OSE Immunotherapeutics SA Announces Acceptance of the US Investigational New Drug Application Obtained by Veloxis Pharmaceuticals, Inc., Its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

OSE Immunotherapeutics SA Announce the Continuation of Its Phase 2 Trial Testing Anti-Il-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis After the Interim Futility Analysis

OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, Its Multi-Target T-Cell Anti-COVID Vaccine

First half 2021 earnings released: €0.64 loss per share (vs €0.21 loss in 1H 2020)

OSE Immunotherapeutics SA to Present Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Esmo 2021

OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi in Combination with Pembrolizumab in Ovarian Cancer

Servier and OSE Immunotherapeutics SA Announces Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

OSE Immunotherapeutics SA Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

Ose Immunotherapeutics and the Fort Foundation Announce Initiation of A Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

OSE Immunotherapeutics SA and Boehringer Ingelheim to Present Positive Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Asco 2021

Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA (ENXTPA:OSE).

OSE Immunotherapeutics Sa and ARCAGY - GINECO Announces Initiation of A Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

OSE Immunotherapeutics SA to Present New Data Reflecting Expansion and Progress on Its Immuno-Oncology and Inflammation Preclinical Portfolio At the 2021 Aacr Annual Meeting

OSE Immunotherapeutics SA Announces Granting of First European Patent Protecting Anti-Il-7 Receptor Antagonist OSE-127/S95011

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

OSE Immunotherapeutics Receives €1.3 Million Milestone Payment from Bpifrance for OSE-127/S95011

OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011

OSE Immunotherapeutics Receives €5.2 Million in Public Funding for the Clinical Development of CoVepiT, its Second Generation COVID-19 Vaccine

OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation

OSE Immunotherapeutics Provides COVID-19 Vaccine Update on Covepit